KalVista Pharmaceuticals (KALV) Enterprise Value (2016 - 2025)
Historic Enterprise Value for KalVista Pharmaceuticals (KALV) over the last 10 years, with Q4 2024 value amounting to -$268.3 million.
- KalVista Pharmaceuticals' Enterprise Value changed N/A to -$268.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$268.3 million, marking a year-over-year change of. This contributed to the annual value of -$210.4 million for FY2024, which is N/A changed from last year.
- KalVista Pharmaceuticals' Enterprise Value amounted to -$268.3 million in Q4 2024.
- In the past 5 years, KalVista Pharmaceuticals' Enterprise Value ranged from a high of -$50.3 million in Q1 2021 and a low of -$268.3 million during Q4 2024
- For the 4-year period, KalVista Pharmaceuticals' Enterprise Value averaged around -$117.5 million, with its median value being -$91.9 million (2020).
- Per our database at Business Quant, KalVista Pharmaceuticals' Enterprise Value skyrocketed by 4021.68% in 2020 and then plummeted by 4138.91% in 2024.
- Quarter analysis of 4 years shows KalVista Pharmaceuticals' Enterprise Value stood at -$55.9 million in 2020, then rose by 9.96% to -$50.3 million in 2021, then crashed by 105.07% to -$103.2 million in 2023, then tumbled by 160.09% to -$268.3 million in 2024.
- Its last three reported values are -$268.3 million in Q4 2024, -$135.8 million for Q4 2024, and -$174.3 million during Q3 2024.